Acclimatization Mechanisms During Ascent to 7500m

This study has been completed.

First Received: January 15, 2008 Last Updated: January 26, 2008 History of Changes

Sponsor:	University of Zurich
Collaborator:	Swiss National Science Foundation
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00603122

Purpose

The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.

Condition	Intervention
Acute Mountain Sickness	Behavioral: ascent protocol

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Active Control, Parallel Assignment
Official Title:	Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology

Further study details as provided by University of Zurich:

Primary Outcome Measures:

acute mountain sickness [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

mountaineering success, oxygen saturation, breathing pattern [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Enrollment:	37
Study Start Date:	March 2005
Study Completion Date:	December 2005
Primary Completion Date:	December 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental fast ascent	Behavioral: ascent protocol ascent protocol for the two groups has different acclimatization time
2: Active Comparator slow ascent	Behavioral: ascent protocol ascent protocol for the two groups has different acclimatization time

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy, physically fit subject
Mountaineering experience

Exclusion Criteria:

Any type of cardiac or respiratory disease
Regular intake of any medication
History of high altitude pulmonary oedema
Severe acute mountain sickness at altitudes below 3500m or high altitude cerebral oedema.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00603122

Sponsors and Collaborators

University of Zurich

Swiss National Science Foundation

Investigators

Principal Investigator:

Konrad E Bloch, MD

Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland

More Information

No publications provided

Responsible Party:	University Hospital Zurich ( Konrad E. Bloch )
Study ID Numbers:	EK-1189, SNSF 3200B0-108300
Study First Received:	January 15, 2008
Last Updated:	January 26, 2008
ClinicalTrials.gov Identifier:	NCT00603122 History of Changes
Health Authority:	Switzerland: Swissmedic

Keywords provided by University of Zurich:

altitude illness
hypoxia

Additional relevant MeSH terms:

Altitude Sickness
Respiratory Tract Diseases
Respiration Disorders

ClinicalTrials.gov processed this record on November 30, 2009